BioSyent Inc.

TSXV:RX Voorraadrapport

Marktkapitalisatie: CA$132.5m

BioSyent Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

BioSyent has a total shareholder equity of CA$35.4M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$41.5M and CA$6.1M respectively. BioSyent's EBIT is CA$8.3M making its interest coverage ratio -7.3. It has cash and short-term investments of CA$17.4M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

CA$0

Schuld

Rente dekkingsratio-7.3x
ContantCA$17.41m
AandelenCA$35.42m
Totaal verplichtingenCA$6.06m
Totaal activaCA$41.48m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Aug 30
BioSyent's (CVE:RX) Dividend Will Be CA$0.045

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

Mar 22
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Feb 09
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14
BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19
BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17
Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18
BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07
BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17
BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02
Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Analyse van de financiële positie

Kortlopende schulden: RX's short term assets (CA$30.1M) exceed its short term liabilities (CA$4.9M).

Langlopende schulden: RX's short term assets (CA$30.1M) exceed its long term liabilities (CA$1.2M).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: RX is debt free.

Schuld verminderen: RX has not had any debt for past 5 years.

Schuldendekking: RX has no debt, therefore it does not need to be covered by operating cash flow.

Rentedekking: RX has no debt, therefore coverage of interest payments is not a concern.

Balans

Ontdek gezonde bedrijven

7D

1Y

7D

1Y

7D

1Y